在小鼠中,XII因子和prekallikrein促进微血管炎症和牛皮
Yurong Zhang1, Zengrong Chen1, Junyan Guo1,2
1State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
British journal of pharmacology
|June 14, 2024
概括
激活XII因子通过增加布拉迪基宁,促进牛皮,导致微血管炎症. 抑制这种途径为牛皮提供了一个新的治疗策略.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 血管生物学 血管生物学
背景情况:
- 牛皮是一种自身免疫性皮肤疾病,其特点是微血管异常和 elevated bradykinin.
- 对XII因子的接触激活启动了kallikrein-kinin级联,导致炎症和血管.
- 在牛皮病的发病过程中XII因子的具体作用仍然未被探索.
研究的目的:
- 为了研究因子XII和prekallikrein在小鼠皮病的imiquimod诱导模型中的作用.
- 评估XII因子缺乏对皮肤微循环和牛皮病变发展的影响.
- 评估一种新型抗体,以阻止XII因子激活,作为潜在的牛皮治疗方法.
主要方法:
- 在牛皮的小鼠模型中检查了XII因子或prekallikrein遗传缺陷的影响.
- 评估皮肤微循环,使用静脉共聚焦显微镜和激光多普勒流量计.
- 测试了一种针对XII因子激活的新型抗体,用于预防和治疗牛皮.
主要成果:
- 在牛皮的皮肤中,XII因子的表达显著上调.
- 遗传删除XII因子或prekallikrein减弱的牛皮病变和相关的微血管炎症.
- 用抗体阻断XII因子减轻了实验性牛皮,并抑制了微血管炎症.
结论:
- 激活XII因子驱动牛皮病原体通过依赖prekallikrein的布拉迪基宁的形成,调解微血管炎症.
- 向XII因子接触激活是牛皮的一种有前途的新疗法策略.
- 布拉迪基宁B2受体对抗作用模仿了因子XII/prekallikrein缺乏的保护作用.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
10.9K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.9K
01:16Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K